TheProfitWatch

BTAI - BioXcel Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
1.85 0.03 (1.89%) 0.0 (0.0%) 0.0 (0.0%) 0.0 (0.26%) -0.08 (-4.32%) 0.14 (7.71%) -0.02 (-1.08%) -0.02 (-1.12%)

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-2.45
Diluted EPS:
-2.45
Basic P/E:
-0.7694
Diluted P/E:
-0.7694
RSI(14) 1m:
75.0
VWAP:
1.89
RVol:

Events

Period Kind Movement Occurred At

Related News